Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02120417
Title A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements No
Sponsors Incyte Corporation

Her2-receptor negative breast cancer


Capecitabine + Ruxolitinib


Age Groups: adult
Covered Countries USA | ITA | FRA | ESP

No variant requirements are available.